Peer-influenced content. Sources you trust. No registration required. This is HCN.
JAMA Network
The final results of this randomized clinical trial of 493 patients with pancreatic ductal adenocarcinoma (PDAC) showed that treatment with modified FOLFIRINOX as opposed to gemcitabine significantly increased overall survival (median survival, 53.5 vs. 35.5 months). Younger age, well-differentiated tumors, lower-stage tumors, larger-volume centers, and finishing the prescribed course of therapy all predicted better survival; early disease relapse was an adverse prognostic factor for overall survival from relapse.
Oncology, Medical November 28th 2022
The 100-μg dose of the ERBB2 ICD plasmid-based vaccine was associated with the generation of ERBB2-specific type 1 T cells in the majority of patients with ERBB2-expressing breast cancer in this phase 1 nonrandomized clinical trial, and it is currently being assessed in randomized phase 2 trials.
Oncology, Medical November 7th 2022
Journal of Clinical Oncology
Radiation field size and the effects of ADT sequencing for various oncologic end goals interact significantly. Concurrent/adjuvant ADT was linked to considerably better metastasis-free survival, prostate cancer-specific mortality, and overall survival with prostate-only radiation; the impact of ADT sequencing with whole-pelvic radiation is less clear, with neither consistently showing a benefit.
Oncology, Medical October 31st 2022
Cancer Therapy Advisor
According to a study presented at the 2022 ASCO Quality Care Symposium, 27% of 159 patients in the sample who received inpatient immune checkpoint inhibitor (ICI) treatment passed away while still in the hospital, with the median overall survival for the entire group being 47 days. Thoracic or head and neck cancers (27%) were the most prevalent, with gastrointestinal cancers (20%), hematologic malignancies (18%), genitourinary cancers (17%), and melanoma (11%) rounding out the rest.
Hematology/Oncology October 31st 2022
MDLinx
This review of three recent publications in Schizophrenia Bulletin, Expert Opinion in Pharmacotherapy, and Frontiers in Psychiatry highlights some potential opportunity to change standard practice and improve patient outcomes. Emerging research indicates that once-daily dosing before bed is likely effective, reduces adverse effects, and boosts adherence. Furthermore, when switching agents, immediate discontinuation may be preferable, with no need to taper.
Psychiatry October 20th 2022
In this study involving 452 patients with diagnoses of MDD, GAD, and PTSD, IM ketamine reduced depression by 38% and anxiety by 50%, with persistence over 7 months of maintenance therapy.
Family Medicine/General Practice October 20th 2022